MX374840B - Analogos de bicalutamida o (s)-bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acumulo lisosomal o glucogenosis. - Google Patents

Analogos de bicalutamida o (s)-bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acumulo lisosomal o glucogenosis.

Info

Publication number
MX374840B
MX374840B MX2016008283A MX2016008283A MX374840B MX 374840 B MX374840 B MX 374840B MX 2016008283 A MX2016008283 A MX 2016008283A MX 2016008283 A MX2016008283 A MX 2016008283A MX 374840 B MX374840 B MX 374840B
Authority
MX
Mexico
Prior art keywords
bicalutamide
exocytosis
treatment
lysosomal storage
glycogenosis
Prior art date
Application number
MX2016008283A
Other languages
English (en)
Other versions
MX2016008283A (es
Inventor
Rubió Antonia Ribes
Montiel Antonio Ferrer
Obiols Berta Ponsati
Josep Farrera-Sinfreu
Mas Laura Gort
Borrel Leslie Matalonga
Martínez Roberto Pascual
Original Assignee
Bcn Peptides Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50238086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX374840(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bcn Peptides Sa filed Critical Bcn Peptides Sa
Publication of MX2016008283A publication Critical patent/MX2016008283A/es
Publication of MX374840B publication Critical patent/MX374840B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16—Isothiocyanates
    • C07C331/28—Isothiocyanates having isothiocyanate groups bound to carbon atoms of six-membered aromatic rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7057—(Intracellular) signaling and trafficking pathways
    • G01N2800/7066—Metabolic pathways

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Food Science & Technology (AREA)
  • Nanotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona un tratamiento para las enfermedades de acúmulo lisosomal y las glucogenosis mediante compuestos que promueven la exocitosis, preferentemente la exocitosis lisosomal. El tratamiento de células de pacientes afectados por distintos tipos de enfermedades de acúmulo lisosomal con compuestos que promueven la exocitosis da lugar a una disminución del acúmulo tóxico de sustratos en los lisosomas y permite el tratamiento, prevención y alivio de los síntomas de muchos desórdenes de acúmulo lisosomal.
MX2016008283A 2013-12-23 2014-12-19 Analogos de bicalutamida o (s)-bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acumulo lisosomal o glucogenosis. MX374840B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382541 2013-12-23
PCT/EP2014/078745 WO2015097088A1 (en) 2013-12-23 2014-12-19 Bicalutamide analogs or (s)-bi calutam ide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis

Publications (2)

Publication Number Publication Date
MX2016008283A MX2016008283A (es) 2016-09-08
MX374840B true MX374840B (es) 2025-03-06

Family

ID=50238086

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008283A MX374840B (es) 2013-12-23 2014-12-19 Analogos de bicalutamida o (s)-bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acumulo lisosomal o glucogenosis.

Country Status (21)

Country Link
US (1) US11571407B2 (es)
EP (1) EP3086784B9 (es)
JP (1) JP6546923B2 (es)
KR (1) KR102128145B1 (es)
CN (1) CN105828811B (es)
AU (1) AU2014372690B2 (es)
CA (1) CA2934772C (es)
CL (1) CL2016001210A1 (es)
DK (1) DK3086784T3 (es)
ES (1) ES2732308T3 (es)
HU (1) HUE043959T2 (es)
IL (1) IL245789B (es)
LT (1) LT3086784T (es)
MX (1) MX374840B (es)
MY (1) MY182903A (es)
NZ (1) NZ720499A (es)
PH (1) PH12016501168A1 (es)
PL (1) PL3086784T3 (es)
PT (1) PT3086784T (es)
RU (1) RU2685269C2 (es)
WO (1) WO2015097088A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
US20190076376A1 (en) 2015-07-10 2019-03-14 University Of Miami Methods for treating mucopolysaccharidosis
WO2017096049A1 (en) 2015-12-03 2017-06-08 The University Of North Carolina At Pembroke Materials for cathepsin b enhancement and methods of use
CA3010205A1 (en) 2015-12-30 2017-07-06 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of pompe disease
NZ748599A (en) * 2016-04-21 2022-08-26 Baylor College Medicine Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction
EP3624831B1 (en) 2017-05-15 2023-03-29 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase
EP4285921B1 (en) * 2018-04-27 2025-10-08 The Medical College of Wisconsin, Inc. Use of lentivector-transduced t-rapa cells for amelioration of lysosomal storage disorders
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
CN112807302A (zh) * 2021-02-05 2021-05-18 重庆西南果品营养研究院 橘皮素在制备控制人体血尿酸水平的药物或食品中的新用途
CN115678934A (zh) * 2022-11-07 2023-02-03 陕西科技大学 一种利用大肠杆菌和谷氨酸棒杆菌共培养合成圣草酚的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE468159B (sv) 1991-03-25 1992-11-16 Alfa Laval Thermal Ab Foerfarande foer att belaegga vaermeoeverfoeringsplattor i en plattvaermevaexlare med ett skikt av ytskyddande material
US6071957A (en) 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
AU7604798A (en) * 1997-05-30 1998-12-30 University Of Tennessee Research Corporation, The Non-steroidal agonist compounds and their use in male hormone therapy
US6019957A (en) * 1997-06-04 2000-02-01 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
CN1646479A (zh) * 2002-02-28 2005-07-27 田纳西大学研究基金会 不可逆选择性雄激素受体调节剂及其使用方法
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
US20110237664A1 (en) 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
ATE460154T1 (de) * 2006-03-14 2010-03-15 Lidds Ab Bioresorbierbare zusammensetzung mit kontrollierter freisetzung
EP2024745B1 (en) * 2006-05-16 2015-07-08 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for fabry disease
JP5215300B2 (ja) 2006-07-12 2013-06-19 ユニバーシティ オブ テネシー リサーチ ファウンデーション 置換アシルアニリドおよびそれらの使用方法
WO2010015816A2 (en) 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
DK3395372T3 (da) * 2009-02-20 2022-04-19 Enhanx Biopharm Inc System til afgivelse af glutathion-baseret medikament
AU2010305284A1 (en) * 2009-10-06 2012-05-03 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
AU2011223706A1 (en) * 2010-03-05 2012-09-20 Baylor Research Institute Involvement of androgen/androgen receptor pathway in Fabry disease
CN103764824B (zh) * 2011-06-20 2018-04-24 西奈山医学院 粘多糖贮积症和其它溶酶体病症的抗TNF-α疗法
US9393221B2 (en) 2011-07-20 2016-07-19 The General Hospital Corporation Methods and compounds for reducing intracellular lipid storage

Also Published As

Publication number Publication date
HUE043959T2 (hu) 2019-09-30
LT3086784T (lt) 2019-06-25
RU2685269C2 (ru) 2019-04-17
KR20160095174A (ko) 2016-08-10
DK3086784T3 (da) 2019-06-17
WO2015097088A1 (en) 2015-07-02
CA2934772A1 (en) 2015-07-02
MX2016008283A (es) 2016-09-08
KR102128145B1 (ko) 2020-06-30
CL2016001210A1 (es) 2016-12-16
NZ720499A (en) 2020-04-24
EP3086784B9 (en) 2019-10-16
US20160317489A1 (en) 2016-11-03
CA2934772C (en) 2021-04-27
PL3086784T3 (pl) 2019-09-30
AU2014372690A1 (en) 2016-06-09
ES2732308T3 (es) 2019-11-21
IL245789B (en) 2020-01-30
AU2014372690B2 (en) 2019-10-03
RU2016125883A (ru) 2018-01-30
CN105828811A (zh) 2016-08-03
PH12016501168B1 (en) 2016-07-18
PH12016501168A1 (en) 2016-07-18
RU2016125883A3 (es) 2018-07-31
MY182903A (en) 2021-02-05
JP6546923B2 (ja) 2019-07-17
JP2017503781A (ja) 2017-02-02
EP3086784B1 (en) 2019-03-27
PT3086784T (pt) 2019-06-27
EP3086784A1 (en) 2016-11-02
IL245789A0 (en) 2016-07-31
US11571407B2 (en) 2023-02-07
CN105828811B (zh) 2022-04-08

Similar Documents

Publication Publication Date Title
MX374840B (es) Analogos de bicalutamida o (s)-bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acumulo lisosomal o glucogenosis.
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
MX2015008241A (es) Metodos para el tratamiento de espasmos gastrointestinales.
BR112016023815A2 (pt) composições tópicas para o alívio da dor, produção e uso
ECSP16078782A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
CL2017000394A1 (es) Composición que contiene cineol para la administración nasal
EP3009426A4 (en) 4-ALKYNYL-IMIDAZOLE DERIVATIVE AND MEDICAMENT THEREFORE AS AN ACTIVE SUBSTANCE
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
EP2868741A4 (en) AQUEOUS TREATMENT LIQUID
EP3050884A4 (en) Novel chemical compounds (variants) and the use thereof to treat oncological diseases
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
UY35745A (es) Derivados sustituidos de fenilalanina
HRP20181554T1 (hr) Tauroursodezoksikolna kiselina (tudca), namijenjena upotrebi u liječenju neurodegenerativnih poremećaja
FI20155991A7 (fi) Elektrodimoduuli, sähkökemiallinenreaktori, ja vedenkäsittelylaite
CL2015001681A1 (es) Unidad solida con alto contenido en fexofenadina; procedimiento de preparacion; y uso de la misma como antihistaminico, broncodilatador y/o para el tratamiento de alergias y/o urticarias.
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
FR3027522B1 (fr) Composition poreuse chargee en principe actif
BR112014009492A2 (pt) eletrodo de estimulação de orientação automática
FR3000112B1 (fr) Structure de securite.

Legal Events

Date Code Title Description
FG Grant or registration